Retail buyers in Western Europe and Latin America placed renewed purchase orders for Matrixyl 3000, Argireline, and related palmitoyl oligopeptides in Q1 2026, favoring INCI names with established consumer recognition over newly patented sequences with limited shelf-education support. Kilogram-scale cosmetic grades with three-week replenishment cycles remain the norm; differentiation is shifting to delivery systems rather than novel amino-acid chains.

Sourcing teams should verify sequence identity, salt form, and fatty-acid conjugation position by independent LC-MS—not supplier trade name alone—when qualifying alternate vendors.